Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 21,100 shares, a decline of 86.8% from the October 15th total of 159,900 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 15,490,000 shares, the short-interest ratio is currently 0.0 days.
Bluejay Diagnostics Price Performance
Shares of BJDX traded up $0.01 during mid-day trading on Tuesday, reaching $0.11. 38,953,451 shares of the company’s stock were exchanged, compared to its average volume of 5,155,719. The business’s fifty day simple moving average is $0.12 and its 200-day simple moving average is $1.43. Bluejay Diagnostics has a 52-week low of $0.07 and a 52-week high of $31.28. The stock has a market capitalization of $1.79 million, a PE ratio of 0.00 and a beta of 0.73.
Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($5.12) earnings per share (EPS) for the quarter.
Institutional Trading of Bluejay Diagnostics
Bluejay Diagnostics Company Profile
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Featured Articles
- Five stocks we like better than Bluejay Diagnostics
- 10 Best Airline Stocks to Buy
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Pros And Cons Of Monthly Dividend Stocks
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Financial Services Stocks Investing
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.